Compare Home Depot Inc (HD) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Illumina, Inc. — how do they compare? Home Depot Inc trades at $290.89 (market cap $294.79B), while Illumina, Inc. trades at $277.61 (market cap $39.95B). The key difference: Home Depot Inc is far larger — about 7.4× Illumina, Inc.'s market cap, and Home Depot Inc pays a 3.15% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and Illumina, Inc. for 83 Days on average.
| HD | ILMN | |
|---|---|---|
Market Cap | $294.79B | $39.95B |
Volume | 8,693,917 | 3,169,503 |
Sector | Consumer Cyclical | Health |
52-Week High | $391.90 | $293.69 |
52-Week Low | $281.15 | $91.00 |
Typical Hold Time | 139 Days | 83 Days |
Enterprise Value | $355.27B | $41.31B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $290.74, up 1.74% on the day, reflecting positive momentum amid a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats, a P/E of 20.68, and a net income margin of 8.41%. Recent cash flow trends indicate significant investment activity, while analyst consensus remains optimistic with a $379.93 price target. News highlights institutional adjustments and focus on Pro segment growth amid housing market pressures.
The outlook for HD is supported by solid profitability and analyst confidence, but risks include weakening big-ticket demand and margin pressures from investments. Housing market volatility and rising mortgage rates present headwinds, yet long-term prospects are bolstered by strategic initiatives and resilient Pro customer demand.
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
